| Drug ID: | Drug102 |
|---|---|
| Drug Name: | Ferrous fumarate |
| CID: | 6433164 |
| DrugBank ID: | DB14491 |
| Modality: | Small Molecule |
| Groups: | NULL |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT05581420, , NCT05456932, , NCT06321887, |
| Molecular Formula: | C4H2FeO4 |
| Molecular Weight: | 169.9 g/mol |
| Isomeric SMILES: | C(=C/C(=O)[O-])\\C(=O)[O-].[Fe+2] |
| Synonyms: | Ferrous fumarate; 141-01-5; Ercoferro; Ferrofume; Hemoton; Toleron; Tolferain; Tolifer; Cpiron; Fumar |
| Phase 0: | 1 |
| Phase 1: | 5 |
| Phase 2: | 7 |
| Phase 3: | 15 |
| Phase 4: | 18 |
| Description: | NULL |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| dt870 | 6433164 | Ferrous Fumarate | 7037 | TFRC | Homo sapiens (human) | 16564538 | None |
| dt871 | 6433164 | Ferrous Fumarate | 54583 | EGLN1 | Homo sapiens (human) | 16649251 | None |
| dt872 | 6433164 | Ferrous Fumarate | 55869 | HDAC8 | Homo sapiens (human) | 16681389 | None |
| dt873 | 6433164 | Ferrous Fumarate | 51327 | AHSP | Homo sapiens (human) | 16901899 | None |
| dt874 | 6433164 | Ferrous Fumarate | 3040 | HBA2 | Homo sapiens (human) | 16901899 | None |
| dt875 | 6433164 | Ferrous Fumarate | 2395 | FXN | Homo sapiens (human) | 16911956 | None |
| dt876 | 6433164 | Ferrous Fumarate | 2495 | FTH1 | Homo sapiens (human) | 17070541 | None |
| dt877 | 6433164 | Ferrous Fumarate | 2237 | FEN1 | Homo sapiens (human) | 20622253 | None |
| dt878 | 6433164 | Ferrous Fumarate | 79661 | NEIL1 | Homo sapiens (human) | 20622253 | None |
| dt879 | 6433164 | Ferrous Fumarate | 252969 | NEIL2 | Homo sapiens (human) | 20622253 | None |
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT06321887 | EffiCacy and sAfEty of Low doSe orAl iRon for Anaemia in IBD | PHASE3 | RECRUITING | Liverpool University Hospitals NHS Foundation Trust | Inflammatory Bowel Disease|Iron Deficiency Anemia | DRUG: Ferrous fumarate syrup 2.5ml/70mg (22.5mg e… | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| EUCTR2018-002982-20-GB | A Pilot Study to assess the efficacy and safety of reduced dose oral iron in the treatment of iron deficiency anaemia in inflammatory bowel disease patients - Efficacy and safety of low dose oral iron for anaemia in IBD (CAESAR) | PHASE4 | Authorised | Royal Liverpool University Hospital | Iron deficiency anaemia in inflammatory bowel dis… | Trade Name: Ferrous Fumarate Syrup Product Name: … | Details |
| EUCTR2012-005644-26-BE | Prospective Open Label study of Parenteral vs Enteral iron in Young IBD patients and Effect on physical fitness - POPEYE study | PHASE4 | Authorised | Atrium Medical Centre | Anemia and fatigue in children with Inflammatory … | Trade Name: Injectafer /ferinject. Pharmaceutical… | Details |
| NCT05581420 | Oral Versus Intravenous Iron in IBD Patients With Anti-inflammatory Therapy. | None | RECRUITING | Leiden University Medical Center | Inflammatory Bowel Diseases | DRUG: Ferrous fumarate|DRUG: MonoFer | Details |
| NCT05456932 | Predicting Response to Iron Supplementation in Patients With Active Inflammatory Bowel Disease | PHASE4 | UNKNOWN | Leiden University Medical Center | Inflammatory Bowel Diseases|Iron-deficiency|Iron … | DRUG: Intravenous iron|DRUG: Ferric maltol|DRUG: … | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammat…
PMID: 36563900
Year: 2023
Relationship Type:
Treatment
Score: 9.5
OBJECTIVE: To determine whether intravenous (IV) or oral iron suppletion is superior in improving physical fitness in anemic children with inflammato…
Oral ferrous fumarate or intravenous iron sucrose for patients with inflammator…
PMID: 16165718
Year: 2005
Relationship Type:
Treatment
Score: 6.1
BACKGROUND & AIMS: Growth hormone (GH) is used as therapy for inflammatory bowel disease (IBD), but the specific effects on intestine are unknown. T…